Mineral BioSciences’ Totala and Ionicell supplements were flagged as unapproved new drugs and misbranded, with manufacturing violations.
What happened
FDA inspected the Goodyear, AZ facility on November 12-24, 2025, and later reviewed the company’s websites in May 2026 and Facebook and Instagram pages in March 2026. It found claims that Totala and Ionicell treat or manage diabetes complications, blood sugar, blood pressure, and joint pain, making them unapproved new drugs. The inspection also found dietary supplement CGMP (current good manufacturing practice) violations, including insanitary plant conditions, rodent activity in storage areas, missing quality control approvals, incomplete batch records, and unverified supplier certificates.
What FDA found
FDA found website and social media claims that Totala and Ionicell treat or prevent diabetes complications, high blood sugar, high blood pressure, and joint pain, and FDA says they are unapproved new drugs for those uses.
21 U.S.C. 321(g)(1)(B), 321(p), 331(d), 355(a)FDA says the products are misbranded because they lack adequate directions for safe use by a layperson for diseases that need a licensed practitioner’s care.
21 U.S.C. 352(f)(1); 21 CFR 201.5FDA found the plant was not clean or in repair and did not keep pests out, including insulation hanging from the ceiling, a leaking light casing, wall holes, open doors, and rodent activity in product storage and the warehouse.
21 CFR 111.15(b), 111.15(d)(2)Quality control had not signed and approved the written ingredient specifications for (b)(4).
21 CFR 111.105(a)Batch production records for Totala Lemon Lime and Ionicell did not include equipment cleaning times or the initials of people who weighed, verified, added, or verified addition of ingredients.
21 CFR 111.255(b); 111.260(c), (j)(2)(i)-(iv)FDA says the company relied on suppliers’ test certificates without testing (b)(4) ingredients to confirm them, and FDA says identity testing must be done before use, not only occasionally.
21 CFR 111.75(a)(2)(ii)(A); 111.75(a)(1)(i)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of steps taken to address the violations, with documentation and recurrence-prevention plans; if actions are not complete, the company must explain the delay and give a completion date.
Who should pay attention
- brands that buy dietary supplements from this facility
- retailers and online marketplaces selling mineral or fulvic acid supplements
- consumers using these products for blood sugar or blood pressure
This is a summary. Read the original letter on fda.gov.